NOVARTIS $73.12

down -0.17


18/6/2013 04:18 PM  |  NYSE : NVS  |  Industries : Manufacturing / Pharmaceutical and Medicine Manufacturing
Quotes displayed are delayed by 15 minutes. Market data is provided by Telvent DTN
Get Trend Analysis Icon Get NVS Trend Analysis - it has outperformed the S&P 500 by 13%

ETF Alternatives



People viewing NVS also viewed: , , , ,

Competitors

Ticker Name Volume % Change
RXEI RXELITE 45.2K +4.00%
ALSE ALSERES PHARMACEUTICALS 600.0 +1.00%
ALLP ALLIANCE PHARMACEUTICAL 3.5K +0.82%
KVPBQ K-V PHARMACEUTICAL 1.4K +0.82%
HRDN DC BRANDS INTERNATIONAL INC. C 16.7M +0.67%
View All

NVS Stock Analysis

  1.

    Positive Data on Novartis' Jakavi - Analyst Blog

    (NVS,CBST,NVO,INCY )
    Novartis recently presented positive results on oncology drug Jakavi from a three-year follow up analysis of a phase III trial, COMFORT II.

  2. Positive Data on Incyte's Jakafi - Analyst Blog

    (SNTS,INCY,NVS,JAZZ )
    Incyte announced positive long-term data from two ongoing studies on Jakafi.
  3.

    Ariad's Iclusig in GIST Phase II Study - Analyst Blog

    (PFE,NVS,ARIA,JAZZ )
    The study will evaluate Iclusig's efficacy and safety in patients who have failed at least one tyrosine kinase inhibitor therapy.
  4.

    Good News for InterMune - Analyst Blog

    (ELN,SNY,ITMN,NVS )
    The pricing and reimbursement conditions for InterMune's Esbriet was approved in Italy.
  5.

    Encouraging Data on Novartis' Gilenya - Analyst Blog

    (NVS,CBST,NVO,BIIB )
    Novartis recently presented new data on Gilenya from a phase III study, TRANSFORMS.

  6. PDL BioPharma Guides Higher 2Q Royalties - Analyst Blog

    (RHHBY,ELN,PDLI,NVS )
    PDL BioPharma announced that it expects to receive second quarter 2013 royalty revenues of around $143 million.
  7.

    After A Good Run, Novartis Looks Fairly Valued

    (NVS,RHHBY,BMY,MRK,BIIB )
    Novartis is a well-balanced, high-quality pharma with growth credentials, but also a fair valuation today.

  8. Questcor Surges on Drug Acquisition - Analyst Blog

    (SNTS,NVS,SLXP,QCOR )
    Shares of Questcor received a major boost when the company announced the acquisition of development and commercialization rights to Synacthen and Synacthen Depot from Novartis
Free Reports
  1.

    Free Corn and Ethanol Report!

    Learn how you can take advantage of an ethanol-driven bull market in corn.
  2.

    FREE Options Trading Manual

    If you are new to the options market, this free booklet is designed for you!
  3.

    Find the Best Mortgage Rates

    Search and compare the best fixed and adjustable mortgage rates in your area with Bankrate.com.
Marketplace
Trading Center